JP2004513885A5 - - Google Patents

Download PDF

Info

Publication number
JP2004513885A5
JP2004513885A5 JP2002523486A JP2002523486A JP2004513885A5 JP 2004513885 A5 JP2004513885 A5 JP 2004513885A5 JP 2002523486 A JP2002523486 A JP 2002523486A JP 2002523486 A JP2002523486 A JP 2002523486A JP 2004513885 A5 JP2004513885 A5 JP 2004513885A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
kit
compound
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002523486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004513885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/026792 external-priority patent/WO2002018368A1/en
Publication of JP2004513885A publication Critical patent/JP2004513885A/ja
Publication of JP2004513885A5 publication Critical patent/JP2004513885A5/ja
Pending legal-status Critical Current

Links

JP2002523486A 2000-08-30 2001-08-28 ファルネシルタンパク質トランスフェラーゼインヒビターである三環式抗腫瘍化合物 Pending JP2004513885A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
PCT/US2001/026792 WO2002018368A1 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Publications (2)

Publication Number Publication Date
JP2004513885A JP2004513885A (ja) 2004-05-13
JP2004513885A5 true JP2004513885A5 (https=) 2008-09-25

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002523486A Pending JP2004513885A (ja) 2000-08-30 2001-08-28 ファルネシルタンパク質トランスフェラーゼインヒビターである三環式抗腫瘍化合物

Country Status (27)

Country Link
US (1) US20020198216A1 (https=)
EP (1) EP1313725B1 (https=)
JP (1) JP2004513885A (https=)
KR (1) KR20030034161A (https=)
CN (1) CN100384837C (https=)
AR (1) AR033680A1 (https=)
AT (1) ATE359281T1 (https=)
AU (2) AU2001288451C1 (https=)
BR (1) BR0113675A (https=)
CA (1) CA2420673A1 (https=)
CO (1) CO5640109A2 (https=)
DE (1) DE60127846T2 (https=)
EC (1) ECSP034494A (https=)
ES (1) ES2284686T3 (https=)
HK (1) HK1054548B (https=)
HU (1) HUP0302942A3 (https=)
IL (1) IL154528A0 (https=)
MX (1) MXPA03001849A (https=)
NO (1) NO20030918L (https=)
NZ (1) NZ524246A (https=)
PE (1) PE20020486A1 (https=)
PL (1) PL361103A1 (https=)
RU (1) RU2293734C9 (https=)
SK (1) SK2292003A3 (https=)
TW (1) TWI268280B (https=)
WO (1) WO2002018368A1 (https=)
ZA (1) ZA200301545B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2003030908A2 (en) * 2001-10-09 2003-04-17 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
CA2525987A1 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
CN1972712A (zh) * 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
ES2317047T3 (es) 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
US20220257540A1 (en) * 2019-06-28 2022-08-18 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IE68935B1 (en) * 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
TR200101754T2 (tr) * 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri

Similar Documents

Publication Publication Date Title
JP2004513885A5 (https=)
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
CN101641117B (zh) 药物组合物
RU2008117295A (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
RU2008122967A (ru) Имидазопиразины в качестве ингибиторов протеинкиназ
CA3240724A1 (en) Combination of antibody-drug conjugate and atr inhibitor
RU2003108865A (ru) Трициклические противоопухолевые соединения, являющиеся ингибиторами фарнезилпротеинтрансферазы
RU2008150419A (ru) ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ CDK
WO2015138902A1 (en) Combination therapy with glutaminase inhibitors
MXPA05003119A (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
RU2006132288A (ru) Производные пиразолопиримидина, как ингибиторы циклин-зависимой киназы
CA2497544A1 (en) Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
AU2018294351A1 (en) Compositions and methods for modulating hair growth
WO2016014890A1 (en) Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
KR20190040302A (ko) 글루타미나제 억제제와의 병용 요법
MXPA06000191A (es) Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas.
JP2004510733A5 (https=)
EE200000472A (et) Kasvajavastased toimeained
JP2024160336A (ja) トリス構造を有するリンカーを含むリガンド―薬物複合体
US20080214509A1 (en) Methods for enhancing the efficacy of vascular disrupting agents
JP2001526224A5 (https=)
JP2004510733A (ja) 癌細胞死および腫瘍後退を誘導する方法
CA2315693A1 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
CA2191850C (en) Cancerous metastasis inhibitor
JP2021521219A (ja) Bet阻害剤およびプロテアソーム阻害剤を用いる併用療法